NCT05168423 is a Phase 1 clinical trial of CART-EGFR-IL13Ra2 Cells in Glioblastoma, sponsored by University of Pennsylvania.

Who is sponsoring NCT05168423?

NCT05168423 is sponsored by University of Pennsylvania.

What drugs are being tested in NCT05168423?

Interventions in NCT05168423: CART-EGFR-IL13Ra2 Cells.

What condition does NCT05168423 study?

NCT05168423 studies Glioblastoma.

Is NCT05168423 still recruiting?

NCT05168423 is currently active, enrolled. Last updated 13 April 2026.

Last reviewed 2026-04-13 · How we verify

NCT05168423

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM

Active, enrolled Phase 1 Last updated 13 April 2026

What this trial tests

Phase 1 trial testing CART-EGFR-IL13Ra2 Cells in Glioblastoma in 67 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

24 February 2023

Primary endpoint
19 December 2039

19 December 2039

Quick facts

Lead sponsor	University of Pennsylvania
Phase	Phase 1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	67
Start date	24 February 2023
Primary completion	19 December 2039
Estimated completion	19 December 2039
Sites	1 location across United States

Drugs / interventions tested

CART-EGFR-IL13Ra2 Cells — full drug profile →

Conditions studied

Glioblastoma — all drugs for Glioblastoma →

Sponsor

University of Pennsylvania

Who can join

18 and older, any sex, with Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label phase 1 study to assess the safety and feasibility of autologous T cells co-expressing two CARs targeting the cryptic EGFR epitope 806 and IL13Ra2 (referred to as "CART-EGFR-IL13Ra2 cells") in patients with EGFR-amplified glioblastoma, IDH-wildtype that has recurred following prior radiotherapy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results.
Bagley SJ, Logun M, Fraietta JA, Wang X, et al · · 2024 · cited 279× · PMID 38480922 · DOI 10.1038/s41591-024-02893-z
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
Lin H, Liu C, Hu A, Zhang D, et al · · 2024 · cited 232× · PMID 38720342 · DOI 10.1186/s13045-024-01544-7
Immunotherapy for glioblastoma: current state, challenges, and future perspectives.
Liu Y, Zhou F, Ali H, Lathia JD, et al · · 2024 · cited 189× · PMID 39406966 · DOI 10.1038/s41423-024-01226-x
From signalling pathways to targeted therapies: unravelling glioblastoma's secrets and harnessing two decades of progress.
Dewdney B, Jenkins MR, Best SA, Freytag S, et al · · 2023 · cited 60× · PMID 37857607 · DOI 10.1038/s41392-023-01637-8
Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy.
Logun M, Wang X, Sun Y, Bagley SJ, et al · · 2025 · cited 51× · PMID 39657679 · DOI 10.1016/j.stem.2024.11.010
Recent Advances in IL-13Rα2-Directed Cancer Immunotherapy.
Knudson KM, Hwang S, McCann MS, Joshi BH, et al · · 2022 · cited 45× · PMID 35464460 · DOI 10.3389/fimmu.2022.878365
Armored bicistronic CAR T cells with dominant-negative TGF-β receptor II to overcome resistance in glioblastoma.
Li N, Rodriguez JL, Yin Y, Logun MT, et al · · 2024 · cited 42× · PMID 39086131 · DOI 10.1016/j.ymthe.2024.07.020
Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial.
Bagley SJ, Desai AS, Fraietta JA, Silverbush D, et al · · 2025 · cited 40× · PMID 40451950 · DOI 10.1038/s41591-025-03745-0

Verify or expand the search:

Other recruiting trials for Glioblastoma

Currently open trials in the same condition.

NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other University of Pennsylvania trials

Trials by the same sponsor.

NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA · EARLY_PHASE1 · not yet recruiting
NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD · NA · not yet recruiting
NCT07489430 — DaxibotulinumtoxinA for Blepharospasm · Phase 2 · not yet recruiting
NCT07463131 — Negative Income Tax Trial · NA · not yet recruiting
NCT06645769 — Na-Phenylbutyrate VAscular Trial · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05168423 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
Last refreshed: 13 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05168423.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing